Phosphate management in chronic kidney disease

Area of Science:

• Nephrology
• Internal Medicine
• Pharmacology

Background:

• Hyperphosphatemia is a common complication in chronic kidney disease (CKD).
• Phosphate dysregulation contributes to CKD-MBD (mineral and bone disorder).
• Effective phosphate management is crucial for CKD patient outcomes.

Purpose of the Study:

• To review the rationale and evidence for hyperphosphatemia management in CKD.
• To evaluate current and emerging therapeutic strategies for phosphate control.
• To assess the clinical benefits and uncertainties associated with phosphate binders.

Main Methods:

• Literature review of studies on phosphate binders and CKD management.
• Analysis of evidence regarding clinical benefits, including survival data.
• Evaluation of newer agents and dialysis modalities for phosphate control.

Main Results:

• Phosphate binders demonstrate clinical benefit in CKD patients.
• Sevelamer shows particular evidence of improved survival, though the mechanism is unclear.
• Newer agents (iron-based, niacin compounds) and reduced pill burden may offer advantages.
• Frequent nocturnal hemodialysis can aid phosphate control.
• Data on fibroblast growth factor 23 reduction by binders are limited.

Conclusions:

• Understanding phosphate regulation has advanced, with new agents emerging.
• While sevelamer is increasingly supported over calcium-based binders, cost remains a barrier.
• Current evidence supports evolving strategies but does not yet justify widespread practice changes.